Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel monoclonal antibodies for the treatment and diagnosis of cancer. The company is pursuing multiple company and investigator-sponsored clinical programs with its lead immunotherapy candidate bavituximab including the SUNRISE Phase III trial in patients with second-line non-small cell lung cancer. Other indications include front-line non-small cell lung, liver, breast and rectal cancers as well as melanoma. The company is also investigating an imaging agent that represents a potential new approach to imaging cancer. Peregrine has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com) which provides development and biomanufacturing services for both Peregrine and outside customers.
Company Growth (employees)